Related references
Note: Only part of the references are listed.Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer
Wenjing Zhang et al.
CANCER MEDICINE (2022)
Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer
Yichi Zhang et al.
PEERJ (2022)
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
Wenjing Zhang et al.
NPJ PRECISION ONCOLOGY (2022)
Lipid signalling enforces functional specialization of Treg cells in tumours
Seon Ah Lim et al.
NATURE (2021)
High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy
Qiong Lyu et al.
CANCER MEDICINE (2021)
Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
Fuyan Shi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Samuel J. Klempner et al.
ONCOLOGIST (2020)
Fatty acid synthase is a prognostic marker and associated with immune infiltrating in gastric cancers precision medicine
Yangying Zhou et al.
BIOMARKERS IN MEDICINE (2020)
Reprogramming of fatty acid metabolism in cancer
Nikos Koundouros et al.
BRITISH JOURNAL OF CANCER (2020)
The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma
Luciana Y. de Almeida et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
Qinghua Wang et al.
AGING-US (2020)
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun et al.
LUNG CANCER (2019)
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
Feng Wang et al.
JAMA ONCOLOGY (2019)
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
David A. Braun et al.
JAMA ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer
Yekaterina Y. Zaytseva et al.
Oncotarget (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
Dinja T. Kruger et al.
BRITISH JOURNAL OF CANCER (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells
Li Jiang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Fatty acid synthase (FASN) as a therapeutic target in breast cancer
Javier A. Menendez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs
Zhiyuan Niu et al.
NATURE COMMUNICATIONS (2017)
Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells
Amir A. Al-Khami et al.
ONCOIMMUNOLOGY (2017)
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Yakir Guri et al.
CANCER CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
S. J. H. Ricoult et al.
ONCOGENE (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Jaegil Kim et al.
NATURE GENETICS (2016)
The multifaceted roles of fatty acid synthesis in cancer
Florian Roehrig et al.
NATURE REVIEWS CANCER (2016)
Oncotator: Cancer Variant Annotation Tool
Alex H. Ramos et al.
HUMAN MUTATION (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
Mihaela Angelova et al.
GENOME BIOLOGY (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation
Holly K. Bryan et al.
BIOCHEMICAL PHARMACOLOGY (2013)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
Sean J. Humphrey et al.
CELL METABOLISM (2013)
Cellular Fatty Acid Metabolism and Cancer
Erin Currie et al.
CELL METABOLISM (2013)
Lipid accumulation and dendritic cell dysfunction in cancer
Donna L. Herber et al.
NATURE MEDICINE (2010)
A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
Hailan Liu et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype
Shuji Ogino et al.
HUMAN PATHOLOGY (2007)
Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells:: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
JA Menendez et al.
ANNALS OF ONCOLOGY (2005)
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
JA Menendez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes
DC Berwick et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
